OBJECTIVE -Diabetes eliminates the protective effect of female sex on the risk of coronary heart disease (CHD). We assessed sex differences in the treatment of CHD risk factors among patients with diabetes. CONCLUSIONS -Women with diabetes received less treatment for many modifiable CHD risk factors than diabetic men. More aggressive treatment of CHD risk factors in this population offers a specific target for improvement in diabetes care.
RESEARCH DESIGN AND METHODS
Diabetes Care 28:514 -520, 2005D iabetes confers a markedly increased risk of coronary heart disease (CHD) events in both women and men (1) and eliminates the protective effect of female sex on the risk of CHD. In women with and without diagnosed heart disease, diabetes raises the relative risk of heart disease mortality 3-to 10-fold relative to that of women without diabetes (2-6). Despite declining CHD mortality over the last 30 years in the U.S. population overall and in men with diabetes, women with diabetes appear to have experienced an increase in age-adjusted CHD mortality (7).Several pathophysiological mechanisms may contribute to the increased risk of CHD mortality in men and women with diabetes. Patients with type 2 diabetes have an increased incidence of conventional and unconventional CHD risk factors (8,9). Women with diabetes may be subject to even more adverse changes in coagulation, vascular function, and CHD risk factor levels than diabetic men (10 -13).In addition to sex-based physiologic differences, there may also be differences in treatment of CHD risk factors that contribute to increased risk in women with diabetes. Several studies of patients without diabetes have demonstrated disparities in treatment of heart disease and CHD risk factors among women and men in primary care (14,15) and hospital settings (16,17). Treatment disparities have been shown to be related to differences in patient risk factors (18) and physician behavior (19). These differences may persist even after a problem is identified: when women receive treatment, they are often treated less aggressively (20).Treating modifiable CHD risk factors (such as blood pressure and lipids) and using ACE inhibitors and aspirin reduce mortality in diabetes (21-25), which is now considered a CHD equivalent (26). The Heart Protection Study showed an ϳ25% reduction in vascular event rates in all subgroups treated with simvastatin, including patients with diabetes and women, regardless of initial levels of LDL and HDL cholesterol (27). In 2000, the American Diabetes Association (ADA) recommended statin therapy for patients with LDL cholesterol Ͼ100 mg/dl if CHD or multiple risk factors were present, as well as prophylactic use of aspirin and blood pressure control with an ACE inhibitor to delay progression to microalbuminuria (28). Subsequent recommendations are more stringent (29). The American Heart Association, concordant with the latest ADA guidelines, has endorsed an HDL target of Ͼ50 mg/dl and recommends that statins be initiated in women with diabetes, even if LDL is Ͻ...